Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) Sees Large Increase in Short Interest

Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) was the target of a significant growth in short interest in May. As of May 29th, there was short interest totaling 21,287 shares, a growth of 177.5% from the May 14th total of 7,671 shares. Based on an average trading volume of 7,366 shares, the short-interest ratio is currently 2.9 days. Approximately 11.2% of the company’s stock are short sold.

Bitwise MARA Option Income Strategy ETF Price Performance

NYSEARCA:IMRA traded up $0.11 during mid-day trading on Friday, hitting $17.02. 210 shares of the company’s stock were exchanged, compared to its average volume of 5,322. Bitwise MARA Option Income Strategy ETF has a one year low of $11.99 and a one year high of $54.94. The business has a fifty day moving average price of $16.13 and a 200 day moving average price of $15.93. The company has a market cap of $3.23 million, a PE ratio of 340.40 and a beta of 2.88.

Insider Activity

In related news, insider Helen Louise Collins sold 5,000 shares of the business’s stock in a transaction dated Friday, April 17th. The shares were sold at an average price of $47.67, for a total transaction of $238,350.00. Following the sale, the insider owned 25,000 shares of the company’s stock, valued at $1,191,750. The trade was a 16.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Anne Kunkel sold 10,000 shares of the business’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $34.54, for a total transaction of $345,400.00. Following the sale, the director directly owned 51,884 shares in the company, valued at $1,792,073.36. The trade was a 16.16% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 60,000 shares of company stock worth $2,126,550 in the last three months. 37.30% of the stock is currently owned by insiders.

Bitwise MARA Option Income Strategy ETF Company Profile

IMARA Inc, a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2–related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas.